EX-10.11





 Exhibit 10.11 

 
 



 
 August 11th, 2019 

Dr. Jason Blair Litten 
  

	Re:	 Employment Offer Letter 



Dear Jason, 
 On behalf of Artiva Biotherapeutics, Inc. (the
“Company”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (this “Agreement”). These employment terms will be effective as of your start date, which will be August
19th, 2019. This offer is contingent upon references and Board approval. 
 1. Employment Position; Duties. You will be
employed as the Company’s Chief Medical Officer, reporting to the Company’s President & CEO. As Chief Medical Officer, you will have those duties and responsibilities as are customary for this position and as may be directed by
the Company. You will work from the corporate office in La Jolla and your position may require business travel. During your employment, you will devote your full-time best efforts to the business of the Company. 

2. Base Salary; Employee Benefits and Business Expenses. 

(a) Base Salary. Your initial base salary will be paid at the annual rate of $400,000.00 less standard payroll deductions and tax
withholdings. Your base salary will be paid on the Company’s normal payroll schedule. As an exempt salaried employee, you will be required to work the Company’s normal business hours, and such additional time as appropriate for your work
assignments and position. You will not be eligible for extra payment under the overtime laws. 
 (b) Employee Benefits. As a
regular full-time employee, you will be eligible to participate in the Company’s standard employee benefits (pursuant to the terms and conditions of the benefit plans and applicable policies), as they may be terminated or changed from time to
time within the Company’s discretion. 
 (c) Business Expenses. Your legitimate and documented business expenses will be
reimbursed by the Company as provided under its business expense reimbursement policies. 
 3. Annual Bonus. In addition to
base salary, you will be eligible to earn discretionary incentive compensation at an annual target amount of thirty percent (30%) of your base salary in effect during the bonus year. With respect to the annual incentive compensation program,
the Company’s executive team will evaluate and recommend specific annual individual and corporate performance targets, metrics and/or management-by-objectives
(“MBOs”), to be finalized and approved by Company’s Board of Directors (the “Board”), as part of its annual compensation review process. Annual bonuses are paid on an annual basis, after the close of the fiscal
year and after determination by the Board of (a) the level of achievement of the applicable individual and corporate performance targets, metrics and/or MBOs, and (b) the amount of the annual incentive compensation earned by you (if any).
No amount of 

  

			
	Artiva Biotherapeutics, Inc. I 4747 Executive Drive, Suite 1150, San Diego CA	  	// 1















 



 
  

 
annual incentive compensation is guaranteed and, in addition to the other conditions for earning such compensation, you must remain an employee in good standing of the Company on the scheduled
annual incentive compensation payment date in order to be eligible for any annual incentive compensation. This annual incentive compensation program will be the only incentive compensation, commissions, or other bonus program that will apply to you.

 4. Equity Award. As an inducement material to your entering into this Agreement, subject to approval of the Board, the
Company will grant you a number of shares of the Company’s common stock (“Founders Shares”), at a purchase price equal to the fair market value on the date of grant, representing three percent (3%) of the Company on a fully
diluted basis on the date of grant. The Founders Shares will be subject to a repurchase option in favor of the Company, which will lapse at the rate of 25% of the Founders Shares on each of the one year anniversaries of the date of grant; such that
the repurchase option will terminate on the fourth anniversary of the date of grant, subject to your continued employment with the Company. You also will be eligible to participate in and receive additional stock option or equity award grants under
the Company’s equity incentive plans from time to time, in the discretion of the Board, and in accordance with the terms and conditions of the Plan. 

5. Compliance with Confidentiality Agreement and Company Policies. As a condition of employment, you shall sign and comply with
the Company’s standard form of Employee Confidential Information and Invention Assignment Agreement (the “Confidentiality Agreement”). The Confidentiality Agreement shall be deemed fully incorporated into this Agreement by
reference. 
 6. Protection of Third Party Information and Outside Activities. 

(a) Third Party Information. In your work for the Company, you will be expected not to make any unauthorized use or disclosure of
any confidential information or materials, including trade secrets, of any former employer or other third party; and not to violate any lawful agreement that you may have with any third party. By signing this Agreement, you represent that you are
able to perform your job duties within these guidelines, and you are not in unauthorized possession or control of any confidential documents, information, or other property of any former employer. In addition, you represent that you have disclosed
to the Company in writing any agreement you may have with any third party (e.g., a former employer) that may limit your ability to perform your duties to the Company or that could present a conflict of interest with the Company, including but not
limited to disclosure (and a copy) of any contractual restrictions on solicitations or competitive activities. 
 (b) Outside
Activities. During your employment by the Company, you may engage in civic and not-for-profit activities so long as such activities do not interfere with the
performance of your duties hereunder or present a conflict of interest with the Company or its Affiliates. Subject to the restrictions set forth herein, and only with prior written disclosure to and written consent of the Board, you may engage in
other types of business or public activities. The Board may withdraw such consent, if the Board determines, in its sole discretion, that such activities compromise or threaten to compromise the business interests of the Company or its Affiliates or
conflict with your duties to the Company. 
 (c) Non-Competition. During your
employment by the Company, you will not, without the express written consent of the Board, directly or indirectly serve as an officer, director, stockholder, employee, partner, proprietor, investor, joint venturer, associate, representative or


  

			
	Artiva Biotherapeutics, Inc. I 4747 Executive Drive, Suite 1150, San Diego CA	  	// 2















 



 
  

 
consultant of any person or entity engaged in, or planning or preparing to engage in, business activity competitive with any line of business engaged in (or planned to be engaged in) by the
Company or its Affiliates; provided, however, that you may purchase or otherwise acquire up to (but not more than) one percent (1%) of any class of securities of any enterprise (without participating in the activities of such enterprise) if such
securities are listed on any national or regional securities exchange. In addition, you will be subject to certain restrictions (including restrictions continuing after your employment ends) under the terms of your Confidentiality Agreement. 

7. At-Will Employment Relationship. Your employment relationship with the Company is
employment at-will. Accordingly, you may terminate your employment with the Company at any time and for any reason whatsoever simply by notifying the Company; and the Company may terminate your employment at
any time with or without Cause (as defined below) or prior notice. In addition, the Company retains the discretion to modify your other employment terms from time to time, including but not limited to your position, duties, reporting relationship,
work location, compensation (including base salary and incentive compensation terms), and benefits. 
 8. Severance. 

(a) Severance for Qualifying Termination. If (i) your employment is terminated by the Company without Cause, other than due
to your death or disability, and (ii) you satisfy the Release Requirement (defined below), then you will receive the Severance Payments (defined below) as your sole severance benefits, and you will not be eligible for severance benefits under
any other policy, plan or agreement. Specifically, you will receive severance pay in the form of continuation of your final monthly base salary for three (3) months if your termination occurs prior to the Series A Financing and for six
(6) months if your termination occurs subsequent to the Series A Financing, less standard payroll deductions and tax withholdings (the “Severance Payments”). Subject to Section 8(e), the Severance Payments will be paid in
equal installments on the Company’s regular payroll schedule in effect following your termination date, with such payments to begin on the first regular payroll date following the Release Effective Date (as defined below). If the Severance
Payments do not commence with the first regular payroll date following your termination date because the Release Effective Date is later than such first payroll date, the first installment of the Severance Payments you receive will be a “catch
up” payment in the total amount of the Severance Payments you would have received through such payroll date if such payments had begun with the first payroll date after your termination date. 

(b) Release Requirement. To be eligible for the Severance Payments pursuant to Section 8(a) above you must satisfy the
following release requirement (the “Release Requirement”): return to the Company a signed and dated general release of all known and unknown claims in a separation agreement acceptable to the Company (the “Release and
Waiver”) within the applicable deadline set forth therein, but in no event later than forty-five (45) calendar days following your termination date, and permit the Release and Waiver to become effective and irrevocable in accordance
with its terms (such effective date of the Release and Waiver, the “Release Effective Date”). No Severance Payments will be paid hereunder prior to such Release Effective Date. You may be required by the separation agreement to
provide reasonable transitional services as a condition of payment of Severance Payments. 

  

			
	Artiva Biotherapeutics, Inc. I 4747 Executive Drive, Suite 1150, San Diego CA	  	// 3















 



 
  

 (c) Definition of Cause. For purposes of this Agreement,
“Cause” means the occurrence of any one or more of the following: (i) your conviction of, or plea of no contest, or commission of any felony or any crime involving fraud, embezzlement, dishonesty or moral turpitude;
(ii) your attempted commission of, or participation in, a fraud, embezzlement or act of dishonesty (or an attempted fraud or act of dishonesty) that results in (or could result in) material harm to the Company, including but not limited to
material harm to reputational interests; (iii) your violation of a fiduciary duty or duty of loyalty owed to the Company; (iv) your material breach of any contract or agreement between you and the Company, or any material Company policies
that are disclosed or otherwise made available in writing to you prior to such breach; (v) persistent neglect of your job duties, which is not cured within fifteen (15) calendar days after you are provided written notice by the Company
(provided, that such written notice and opportunity to cure are not required if your performance or neglect is not reasonably susceptible to being cured); or (vi) your gross misconduct or material failure to comply with a reasonable written
instruction of the Company. 
 (d) Other. You will not be eligible for any Severance Payments under any circumstances other
than those described herein, including circumstances in which your employment is terminated for Cause, you terminate your employment for any reason, or your employment terminates due to your death or disability. In addition, if you materially breach
any continuing obligations to the Company (including, but not limited to, any material breach of this Agreement or any material breach of the Confidentiality Agreement) during the period of time that you are receiving any Severance Payments, you
will forfeit your entitlement to any then unpaid Severance Payments, and the Company’s obligation to continue to pay or provide such Severance Payments will immediately terminate as of the date of your material breach. 

(e) IRS Code Section 409A. All payments provided hereunder are intended to constitute separate payments for
purposes of Treasury Regulation Section 1.409A-2( b)(2). If the Company determines that any benefits provided under this Agreement constitute “deferred compensation” under Section 409A of the Internal Revenue Code of 1986 as
amended (“Section 409A”), such benefits will not commence in connection with your termination of employment unless such termination also qualifies as a “separation from service” with the Company within
the meaning of Treasury Regulation Section 1.409A-1(h) (without regard to any permissible alternative definition thereunder) (“Separation from Service”). If the Company determines that
any benefits provided under this Agreement constitute “deferred compensation” under Section 409A and you are a “specified employee” of the Company or any affiliate (or any successor entity thereto) within the meaning of
Section 409A(a)(2)(B)(i) of the Code on the date of your Separation from Service, then the payment of any such benefits shall be delayed until the earlier of (i) the date that is six (6) months and one (1) day after the date of
your Separation from Service, or (ii) the date of your death (such date, the “Delayed Payment Date”), and the Company (or the successor entity thereto, as applicable) shall (A) pay to you a lump sum amount equal to the sum
of the benefit payments that otherwise would have been paid to you on or before the Delayed Payment Date, without any adjustment on account of such delay, and (B) continue the benefit payments in accordance with any applicable payment schedules
set forth for the balance of the period specified herein. In addition to the above, to the extent required to comply with Section 409A and the applicable regulations and guidance issued thereunder, if the applicable deadline for you to execute
(and not revoke) the applicable Release and Waiver spans two (2) calendar years, your Severance Payments shall commence to be paid in installments on the first regularly scheduled payroll date that occurs in the second calendar year after the
Release Effective Date of the Release and Waiver. 

  

			
	Artiva Biotherapeutics, Inc. I 4747 Executive Drive, Suite 1150, San Diego CA	  	// 4















 



 
  

 9. Section 280G; Limitations on Payment. 

(a) If any payment or benefit you will or may receive from the Company or otherwise (a “280G Payment”) would (i) any
constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then any
such 280G Payment provided pursuant to this Agreement (a “Payment”) shall be equal to the Reduced Amount. The “Reduced Amount” shall be either (x) the largest portion of the Payment that would result in no
portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking
into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax basis,
of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to
clause (x) of the preceding sentence, the reduction shall occur in the manner (the “Reduction Method”) that results in the greatest economic benefit for you. If more than one method of reduction will result in the same economic
benefit, the items so reduced will be reduced pro rata (the “Pro Rata Reduction Method”). 
 (b) Notwithstanding any
provision of Section 9(a) to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A that would not otherwise be subject to taxes
pursuant to Section 409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows: (i) as a first priority, the
modification shall preserve to the greatest extent possible, the greatest economic benefit for you as determined on an after-tax basis; (ii) as a second priority, Payments that are contingent on future
events (e.g., being terminated without Cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (iii) as a third priority, Payments that are “deferred compensation” within the meaning of
Section 409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A. 

(c) Unless you and the Company agree on an alternative accounting firm or law firm, the accounting firm engaged by the Company for
general tax compliance purposes as of the day prior to the effective date of the Change of Control transaction shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the
individual, entity or group effecting the Change in Control transaction, the Company shall appoint a nationally recognized accounting or law firm to make the determinations required by this Section 10. The Company shall bear all expenses with
respect to the determinations by such accounting or law firm required to be made hereunder. The Company shall use commercially reasonable efforts to cause the accounting or law firm engaged to make the determinations hereunder to provide its
calculations, together with detailed supporting documentation, to you and the Company within fifteen (15) calendar days after the date on which your right to a 280G Payment becomes reasonably likely to occur (if requested at that time by you or
the Company) or such other time as requested by you or the Company. 
 (d) If you receive a Payment for which the Reduced Amount was
determined pursuant to clause (x) of Section 10(a) and the Internal Revenue Service determines thereafter that some 

  

			
	Artiva Biotherapeutics, Inc. I 4747 Executive Drive, Suite 1150, San Diego CA	  	// 5















 



 
  

 
portion of the Payment is subject to the Excise Tax, you agree to promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of
Section 10(a)) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) of Section 10(a), you shall have no obligation to return
any portion of the Payment pursuant to the preceding sentence. 
 10. Dispute Resolution. To ensure the rapid and economical
resolution of disputes that may arise in connection with your employment with the Company, you and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising
from or relating to the enforcement, breach, performance, or interpretation of this Agreement, your employment with the Company, or the termination of your employment with the Company, will be resolved pursuant to the Federal Arbitration Act, 9
U.S.C. §1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration conducted by JAMS, Inc. (“JAMS”) or its successors by a single arbitrator. The
arbitration will be held in San Diego, California, or such other location as then-agreed by the parties. Both you and the Company acknowledge that by agreeing to this arbitration procedure, you each waive the right to resolve any such dispute
through a trial by jury or judge or administrative proceeding. 
 Any such arbitration proceeding will be governed by JAMS’ then applicable
rules and procedures for employment disputes, which will be provided to you upon request. In any such proceeding, the arbitrator shall (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such
relief as would otherwise be permitted by law; and (b) issue a written arbitration decision including the arbitrator’s essential findings and conclusions and a statement of the award. You and the Company shall be entitled to all rights and
remedies that either would be entitled to pursue in a court of law. Nothing in this Agreement is intended to prevent either the Company or you from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such
arbitration pursuant to applicable law. The Company shall pay all filing fees in excess of those which would be required if the dispute were decided in a court of law and shall pay the arbitrator’s fees and any other fees or costs unique to
arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. 

11. General. This Agreement, along with the Confidentiality Agreement, forms the complete and exclusive statement of your
agreement with the Company regarding the subject matter hereof. It supersedes and replaces any other agreements or promises made to you by anyone concerning your employment compensation, benefits and/or terms, whether oral or written. This Agreement
may not be amended or modified except by a written modification signed by you and a duly authorized officer of the Company, with the exception of those changes expressly reserved to the Company’s discretion in this Agreement. This Agreement is
governed by the laws of the state of California, without reference to conflicts of law principles, and it is intended to bind and inure to the benefit of and be enforceable by the Company and its successors and assigns. If any provision of this
Agreement shall be held invalid or unenforceable in any respect, such invalidity or unenforceability shall not affect the other provisions of this Agreement, and such provision will be reformed, construed and enforced so as to render it valid and
enforceable consistent with the general intent of the parties insofar as possible under applicable law. With respect to the enforcement of this Agreement, no waiver of any right hereunder shall be effective unless it is in writing. Any ambiguity in
this Agreement shall not be construed against either party as the drafter. 

  

			
	Artiva Biotherapeutics, Inc. I 4747 Executive Drive, Suite 1150, San Diego CA	  	// 6















 



 
  

 
This Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile signatures shall be equivalent to original signatures. 

To confirm your terms of continuing employment, please sign and date this Agreement and the Confidentiality Agreement and return the fully signed documents to
me. Please let me know if you have any questions. 
 Sincerely, 

ARTIVA BIOTHERAPEUTICS, INC. 
  

			
	By:	 	 /s/ Thomas J. Farrell

		 	Thomas J. Farrell,
		 	President and Chief Executive Officer

 Reviewed, Understood, and Accepted: 
  

							
	 /s/ Jason Blair Litten
	 		 		 	 Aug. 14, 2019

	Dr. Jason Blair Litten	 		 		 	Date


  

			
	Artiva Biotherapeutics, Inc. I 4747 Executive Drive, Suite 1150, San Diego CA	  	// 7















 



 
  

 April 7, 2021 

Jason Litten, MD 
 Re: Amendment No. 1 to
Employment Offer Letter 
 Dear Jason, 
 This letter (this
“Amendment”) amends your Employment Offer Letter with Artiva Biotherapeutics, Inc. (the “Company”), dated August 11, 2019 (the “Offer Letter”), and is effective as of (and is conditioned upon)
the closing of the first underwritten public offering of the equity securities of the Company pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). All capitalized terms
not otherwise defined herein shall have the same meanings as set forth in the Offer Letter. 
 In consideration of the mutual promises, covenants and
conditions hereinafter set forth, and other consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows: 
  

	 	1.	 Amendments 


  

	 	a.	 The first sentence of Section 2(a) of the Offer Letter is hereby amended and restated to read as follows:



 “Your base salary will be paid at the annual rate of $440,000, less standard payroll deductions and tax
withholdings.” 
  

	 	b.	 The first sentence of Section 3 of the Offer Letter is hereby amended and restated to read as follows:



 “In addition to your base salary, you will be eligible to earn discretionary incentive compensation at an annual
target amount of forty percent (40%) of your base salary in effect during the bonus year (the “Annual Bonus”).” 
  

	 	c.	 Section 8 of the Offer Letter is hereby amended and restated in its entirety to read as
follows:     


 8. Severance 

(a) Severance upon Termination without Cause or Resignation with Good Reason. If (i) your employment is terminated by the
Company without Cause (as defined in the Company’s 2020 Equity Incentive Plan, or any successor or replacement plan, the “Plan”), other than due to your death or disability, or you terminate your employment with Good Reason (as
defined in the Plan), (ii) you satisfy the Release Requirement (defined below), and (iii) comply with your obligations under the Confidentiality Agreement, then you will receive the following “Severance Benefits”: (A)
You will receive severance pay in the form of continuation of your final monthly base salary for a period of nine (9) months following your termination date, less standard payroll deductions and tax withholdings (the “Severance
Payments”). Subject to Section 8(e), the Severance Payments will be paid in equal installments on the Company’s regular payroll schedule in effect following your termination date, with such payments to begin on the first regular
payroll date following the Release Effective Date (as defined below). If the Severance Payments do not commence with the first regular payroll date following your termination date because the Release Effective Date is later than such first payroll
date, the first installment of the Severance Payments you receive will be a “catch up” payment in the total amount of the Severance Payments you would have received through such payroll date if such payments had begun with the first
payroll date after your termination date; (B) In 

  
  

			
	Artiva Biotherapeutics, Inc.	  	4747 Executive Drive #1150, San Diego Ca 92121















 



 
  

 
addition, if you timely elect continued coverage under COBRA, the Company will pay the COBRA premiums for you and your eligible dependents until the earlier of either: (i) a period ending
nine (9) months following your termination date or, (ii) the date on which you are no longer eligible for COBRA coverage (such period, the “COBRA Payment Period”). Notwithstanding the foregoing, if the Company determines,
in its sole discretion, that the Company cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act),
the Company shall in lieu thereof pay you a taxable cash amount, which payment shall be made regardless of whether you or your qualifying family members elect COBRA continuation coverage (the “Health Care Benefit Payment”). The
Health Care Benefit Payment shall be paid in installments on the same schedule that the COBRA premiums would otherwise have been paid to the insurer. The Health Care Benefit Payment shall be equal to the amount that the Company otherwise would have
paid for COBRA insurance premiums (which amount shall be calculated based on the premium for the first month of coverage), and shall be paid until the expiration of the COBRA Payment Period. For purposes of this Agreement, (i) references to
COBRA shall be deemed to refer also to analogous provisions of state law and (ii) any applicable insurance premiums that are paid by the Company shall not include any amounts payable by you under an Internal Revenue Code Section 125 health
care reimbursement plan, which amounts, if any, are your sole responsibility; and (C) The vesting and exercisability of all outstanding and unvested equity awards covering the Company’s common stock that are held by you as of
immediately prior to the termination date, to the extent such equity awards would otherwise have vested solely conditioned on your continued services with the Company, shall accelerate vesting in accordance with their applicable vesting schedules as
if you had completed an additional three (3) months of service with the Company as of the termination date. 
 (b) Severance
upon Termination without Cause or Resignation with Good Reason in Connection with a Change of Control. If (i) your employment is terminated by the Company without Cause (as defined in the Plan), other than due to your death or disability,
or you terminate your employment with Good Reason (as defined in the Plan), in each case within a period commencing three (3) months before, or twelve (12) months after a Change of Control (as defined in the Plan), (ii) you satisfy the
Release Requirement (defined below), and (iii) comply with your obligations under the Confidentiality Agreement, then you will receive the following “Change of Control Severance Benefits”: (A) You will receive severance
pay in the form of continuation of your final monthly base salary for a period of twelve (12) months following your termination date, less standard payroll deductions and tax withholdings (the “Change of Control Severance
Payments”). Subject to Section 8(e), the Severance Payments will be paid in equal installments on the Company’s regular payroll schedule in effect following your termination date, with such payments to begin on the first regular
payroll date following the Release Effective Date (as defined below). If the Severance Payments do not commence with the first regular payroll date following your termination date because the Release Effective Date is later than such first payroll
date, the first installment of the Severance Payments you receive will be a “catch up” payment in the total amount of the Severance Payments you would have received through such payroll date if such payments had begun with the first
payroll date after your termination date; (B) In addition, if you timely elect continued coverage under COBRA, the Company will pay the COBRA premiums for you and your eligible dependents until the earlier of either: (i) a period
ending twelve (12) months following your termination date or, (ii) the date on which you are no longer eligible for COBRA coverage (such period, the “COBRA Payment Period”). Notwithstanding the foregoing, if the Company
determines, in its sole discretion, that the Company cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health
Service Act), the Company shall in lieu thereof pay you a taxable cash amount, which payment shall be made regardless of whether you or your qualifying family members elect COBRA continuation 

  
  

			
	Artiva Biotherapeutics, Inc.	  	4747 Executive Drive #1150, San Diego Ca 92121















 



 
  

 
coverage (the “Health Care Benefit Payment”). The Health Care Benefit Payment shall be paid in installments on the same schedule that the COBRA premiums would otherwise have been
paid to the insurer. The Health Care Benefit Payment shall be equal to the amount that the Company otherwise would have paid for COBRA insurance premiums (which amount shall be calculated based on the premium for the first month of coverage), and
shall be paid until the expiration of the COBRA Payment Period. For purposes of this Agreement, (i) references to COBRA shall be deemed to refer also to analogous provisions of state law and (ii) any applicable insurance premiums that are
paid by the Company shall not include any amounts payable by you under an Internal Revenue Code Section 125 health care reimbursement plan, which amounts, if any, are your sole responsibility; (C) In addition, you will receive your
full target Annual Bonus for the fiscal year in which your employment terminates, payable on the first regular payroll date following the Release Effective Date, provided that the Release Requirement has been satisfied; and (D) Effective
as of the later of the termination date or the effective date of the Change of Control, the vesting and exercisability of all outstanding and unvested equity awards covering the Company’s common stock that are held by you as of immediately
prior to such date, to the extent such equity awards would otherwise have vested solely conditioned on your continued services with the Company, shall accelerate vesting in full. For the avoidance of doubt, in no event shall you be entitled to
benefits under both Section 8(a) and this Section 8(b). If you are eligible for benefits under both Section 8(a) and this Section 8(b), you shall receive the benefits set forth in this Section 8(b) and such benefits shall be
reduced by any benefits previously provided to you under Section 8(a). 
 (c) Release Requirement. To be eligible for the
Severance Benefits and Change pursuant to Section 8(a) and the Change of Control Severance Benefits pursuant to Section 8(b) above, you must satisfy the following release requirement (the “Release Requirement”): You must
timely execute and return to the Company a signed and dated general release of all known and unknown claims in a separation agreement acceptable to the Company (the “Release and Waiver”) within the applicable deadline set forth
therein, but in no event later than forty-five (45) calendar days following your termination date, and permit the Release and Waiver to become effective and irrevocable in accordance with its terms (such effective date of the Release and
Waiver, the “Release Effective Date”). No Severance Benefits or Change of Control Severance Benefits will be paid or provided hereunder prior to such Release Effective Date. You may be required by the separation agreement to provide
reasonable transitional services as a condition to receiving the Severance Benefits and/or the Change of Control Severance Benefits. 

(d) Other. You will not be eligible for any Severance Benefits or Change of Control Severance Benefits under any circumstances other
than those described herein, including circumstances in which your employment is terminated for Cause, you terminate your employment for any reason other than Good Reason, or your employment terminates due to your death or disability. In addition,
if you materially breach any continuing obligations to the Company (including, but not limited to, any material breach of this Agreement or any material breach of the Confidentiality Agreement) during the period of time that you are receiving any
Severance Benefits or Change of Control Severance Benefits, as applicable, you will forfeit your entitlement to any then unpaid Severance Benefits and/or Change of Control Severance Benefits, as applicable, and the Company’s obligation to
continue to pay or provide such Severance Benefits and Change of Control Severance Benefits will immediately terminate as of the date of your material breach and you will be required to return to the Company any Severance Benefits and Change of
Control Severance Benefits already provided to you. 

  
  

			
	Artiva Biotherapeutics, Inc.	  	4747 Executive Drive #1150, San Diego Ca 92121















 



 
  

 (e) IRS Code Section 409A. All payments provided hereunder are
intended to constitute separate payments for purposes of Treasury Regulation Section 1.409A-2(b)(2). If the Company determines that any benefits provided under this Agreement constitute “deferred
compensation” under Section 409A of the Internal Revenue Code of 1986 as amended (“Section 409A”), such benefits will not commence in connection with your termination of employment unless such
termination also qualifies as a “separation from service” with the Company within the meaning of Treasury Regulation Section 1.409A- 1(h) (without regard to any permissible alternative definition thereunder) (“Separation from
Service”). If the Company determines that any benefits provided under this Agreement constitute “deferred compensation” under Section 409A and you are a “specified employee” of the Company or any affiliate (or any
successor entity thereto) within the meaning of Section 409A(a)(2)(B)(i) of the Code on the date of your Separation from Service, then the payment of any such benefits shall be delayed until the earlier of (i) the date that is six
(6) months and one (1) day after the date of your Separation from Service, or (ii) the date of your death (such date, the “Delayed Payment Date”), and the Company (or the successor entity thereto, as applicable) shall
(A) pay to you a lump sum amount equal to the sum of the benefit payments that otherwise would have been paid to you on or before the Delayed Payment Date, without any adjustment on account of such delay, and (B) continue the benefit
payments in accordance with any applicable payment schedules set forth for the balance of the period specified herein. In addition to the above, to the extent required to comply with Section 409A and the applicable regulations and guidance
issued thereunder, if the applicable deadline for you to execute (and not revoke) the applicable Release and Waiver spans two (2) calendar years, your Severance Benefits and/or Change of Control Severance Benefits shall commence to be paid in
installments on the first regularly scheduled payroll date that follows the effective date of the Release and Waiver and which also occurs during the second permitted calendar year for returning the effective Release and Waiver. 

2. Miscellaneous. Except as expressly amended hereby, the Offer Letter, as amended by this Amendment, shall continue in full force and effect in
accordance with its terms. This Amendment is governed by the laws of the state of California, without reference to conflicts of law principles. This Amendment may be executed in counterparts, each of which will be deemed an original, but both of
which together will constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other
applicable law) or other transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

Please acknowledge your agreement with this Amendment by signing below. 

Sincerely, 
  

			
	ARTIVA BIOTHERAPEUTICS, INC.


 
			
		
	By:	 	 /s/ Fred Aslan, MD

	Name: Fred Aslan, MD
	Title:   Chief Executive Officer & President
	
	Acknowledged and Agreed:
	
	 /s/ Jason Litten, MD

	Jason Litten, MD



  
  

			
	Artiva Biotherapeutics, Inc.	  	4747 Executive Drive #1150, San Diego Ca 92121